Pielenhofer, Jonas; Meiser, Sophie Luise; Gogoll, Karsten et al.
Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal ProductPHARMACEUTICS. Bd. 15. H. 2. 2023
Schlenk, R. F.; Weber, D.; Krzykalla, J. et al.
Randomized phase-III study of low-dose cytarabine and etoposide? plus ?/- all-<i>trans</i> retinoic acid in older unfit patients with <i>NPM1</i>-mutated acute myeloid leukemiaSCIENTIFIC REPORTS. Bd. 13. H. 1. 2023
Nowakowski, Grzegorz S.; Yoon, Dok Hyun; Mondello, Patrizia et al.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaANNALS OF HEMATOLOGY. Bd. 102. H. 7. 2023 S. 1773-1787
Hess, Georg; Vucinic, Vladan; Rejeski, Kai et al.
Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss AnalysisBLOOD. Bd. 142. 2023
Zueger, Andrea; Fischbeck, Sabine; Weber, Martin et al.
Revision of the Advanced Cancer Patients' Distress Scale (ACPDS): a mixed-methods study among palliative patients and healthcare professionals in GermanyBMJ OPEN. Bd. 13. H. 4. 2023
Topp, Max; Dlugosz-Danecka, Monika; Skotnicki, Aleksander B. et al.
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesTRIALS. Bd. 24. H. 1. 2023
Althoff, Friederike C.; Schaefer, Lisa V.; Acker, Fabian et al.
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFRONTIERS IN ONCOLOGY. Bd. 13. 2023
Heidegger, Simon; Stritzke, Florian; Dahl, Sarah et al.
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapyCELL REPORTS MEDICINE. Bd. 4. H. 9. 2023
Kropp, Korbinian N.; Fatho, Martina; Huduti, Enes et al.
Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptorsFRONTIERS IN IMMUNOLOGY. Bd. 14. 2023
Rejeski, Kai; Wang, Yucai; Albanyan, Omar et al.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLAMERICAN JOURNAL OF HEMATOLOGY. 2023